JIN Yang Pharmaceutical KRX:007370KOSDAQ
진양제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, JIN Yang Pharmaceutical reported revenue of ₩32.6bn, up 8.2% year on year, and operating profit of ₩4.2bn. JIN Yang Pharmaceutical (진양제약) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 1 article.
Filing signals Profit +50% Screener
JIN Yang Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩32.6bn | +8.2% | ₩4.2bn margin 12.9% | ₩2.2bn |
| Q1 2026 | ₩32.4bn | +4.7% | ₩3.4bn margin 10.4% | ₩2.3bn |
| Q4 2025 derived | ₩30.3bn | +13.1% | −₩2.9bn margin −9.4% | ₩19.3bn |
| Q3 2025 | ₩29.2bn | -7.5% | −₩940m margin −3.2% | −₩991m |
| Q2 2025 | ₩30.2bn | +9.8% | ₩2.5bn margin 8.2% | ₩1.7bn |
| Q1 2025 | ₩30.9bn | +13.3% | ₩3.8bn margin 12.4% | ₩2.3bn |
| Q4 2024 derived | ₩26.8bn | +10.7% | ₩3.1bn margin 11.5% | ₩2.5bn |
| Q3 2024 | ₩31.6bn | +31.4% | ₩4.4bn margin 13.8% | ₩22.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
JIN Yang Pharmaceutical top stories 2 weeks, by number of outlets
- 1